Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?
Article first published online: 6 DEC 2005
Copyright © 1989 American Association for the Study of Liver Diseases
Volume 10, Issue 5, pages 893–895, November 1989
How to Cite
Morgan, D. J. and Smallwood, R. A. (1989), Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?. Hepatology, 10: 893–895. doi: 10.1002/hep.1840100525
- Issue published online: 6 DEC 2005
- Article first published online: 6 DEC 2005
Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases. Galactose blood clearance, which may be taken as effective hepatic blood flow, decreased by approximately 30% in patients with cirrhosis (12.49 ± 0.76 ml/min/kg; mean ± SE; n = 17) compared with normal subjects (18.17 ± 1.03 ml/min/kg; n = 5). In patients with cirrhosis, intrinsic clearances of antipyrine (9.178 ± 0.14 ml/min/kg; n = 17) and indocyanine green (6.19 ± 1.38 ml/min/kg; n = 7) showed 61% and 85% reduction, respectively, compared with those of normal subjects (0.462 ± 0.048 ml/min/kg; n = 5; 41.72 ± 7.75 ml/min/kg; n = 5). Considering that indocyanine green and antipyrine are eliminated by different hepatic mechanisms, these mechanisms may not be equally sensitive to decrements in hepatic function. In addition, fractional reductions of intrinsic clearances for these compounds are thus much greater than that of effective hepatic blood flow.